Advertisement

ENOV

Enovis Corporation

Healthcare · USD

Set alert

Price alert · ENOV

All alert types
19.91 USD -2.90 -12.71%
As of Oct 30, 2026 Extended hours 19.85 -0.30%
Bid
19.76 × 700
Ask
19.97 × 800
19.83 Day range 22.26
17.43 52-week range 31.51
YTD
-25.26%
1 year
-35.13%
Open
22.17
Prev close
22.81
Mkt cap
1.15B
Vol
2.52M
Avg vol
1.54M
EPS
-19.23
P/E
0.00
Div yield
0.00%
More statistics
Low
19.83
High
22.26
Forward P/E
5.64
Beta
1.48
Short ratio
7.14
Inst. own
119.13%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
20.13
200-d avg
23.09
1y target
36.08

2Y chart

Chart tools
Interval
ENOV two-year price chart16.725.033.341.549.8Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
1.15B
Enterprise value
2.67B
Trailing P/E
0.00
Forward P/E
5.64
PEG ratio
3.45
Price / sales
0.50
Price / book
0.78
EPS (TTM)
-19.23
Beta
1.48
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-47.97%
Revenue (TTM)
2.30B
Revenue growth
3.20%
Free cash flow
185.94M
Total cash
12.56M
Total debt
1.37B
Return on equity
-54.14%
Shares outstanding
57.67M
Short % of float
24.18%
50-day average
20.13
200-day average
23.09

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 36.08 +81.2% upside
Target (low)
24.00
Target (mean)
36.08
Target (high)
47.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy10
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 0.76681.

Earnings history

Financials — quick view

All financials
ENOV Revenue — quarterly 582.78M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ENOV Net income — quarterly -1.19M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ENOV EPS — quarterly -0.02
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ENOV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Oct 3, 20260.767———
Aug 6, 2026Jul 3, 20260.8470.90+0.05+6.26%
May 7, 2026Apr 3, 20260.820.89+0.07+8.54%
Feb 26, 2026Dec 31, 20250.810.95+0.14+17.28%
Nov 6, 2025Oct 3, 20250.670.75+0.08+11.94%
Aug 7, 2025Jul 4, 20250.740.79+0.05+6.76%

Upgrades / downgrades

ENOV analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026NeedhammainBuyBuy
Sep 2, 2026Wells FargomainOverweightOverweight
Sep 2, 2026CitizensmainMarket OutperformMarket Outperform
Sep 2, 2026Freedom Capital MarketsmainBuyBuy
Sep 1, 2026BTIGmainBuyBuy
Aug 17, 2026Canaccord GenuitymainBuyBuy

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
enovis.com

News

Your note

Sign in to keep a note on ENOV — it syncs with the Stock Master app.

Insider holders

ENOV insider holders
InsiderRelationLatest transactionDateShares held
BERRY PHILLIP BENJAMIN BENChief Financial OfficerStock Award(Grant)Mar 8, 2026158,596
ENGERT OLIVEROfficerPurchaseSep 3, 202663,898
LANG PATRICIA AOfficerStock Award(Grant)Mar 8, 202675,703
MCDONALD DAMIENChief Executive OfficerPurchaseSep 3, 2026247,077
PRYOR DANIEL ALEXISFormerSaleDec 8, 20250
ROSS TERRY DOfficerStock Award(Grant)Mar 8, 202668,477

Institution ownership

ENOV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.85%10,295,666205.91MJun 29, 2026
American Century Companies Inc10.59%6,106,561122.13MJun 29, 2026
Vanguard Portfolio Management LLC6.81%3,926,26878.53MJun 29, 2026
Rubric Capital Management LP6.76%3,900,00078.00MJun 29, 2026
Vanguard Capital Management LLC4.31%2,484,31849.69MJun 29, 2026
State Street Corporation4.27%2,462,78849.26MJun 29, 2026

Fund ownership

ENOV fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%3,431,56968.63MSep 29, 2026
American Century Capital Portfolios, Inc.-Small Cap Value Fund4.54%2,620,00052.40MJun 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Value Fund4.04%2,328,36046.57MJul 30, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.80%2,189,18243.78MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%1,719,53034.39MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.59%1,493,64329.87MSep 29, 2026
Advertisement